Trial Profile

Phase 1, Randomized, Double-blind, Placebo-controlled, Staggered, Parallel, Single and Multiple Ascending Dose and Food Effect Study to Evaluate the Safety and PK of Oral SAT-3247 in Healthy Volunteers and Participants With DMD

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 04 Mar 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs SAT 3247 (Primary)
Indications Duchenne muscular dystrophy; Facioscapulohumeral muscular dystrophy; Muscle injury
Focus Adverse reactions; First in man
Sponsors Satellos Bioscience

24 Feb 2026 According to a Satellos Bioscience media release, data from the trial will be presented at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference, taking place March 8-11 in Orlando, Florida.
10 Oct 2025 According to a Satellos Bioscience media release, company presents tolerability and initial efficacy data at the 30th Annual Congress of the World Muscle Society in Vienna, Austria.
10 Oct 2025 Results presented in the Satellos Bioscience media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com